Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 5/20 | 0.57 |
| ▸ | EGFR | P00533 | 8/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
| ▸ | CTSC | P53634 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | BCL6 | P41182 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449764 | 0.90 | MAPK1 (0.51) | AXLEGFRMAPK1ERBB2HPGD | |
| SCHEMBL3452720 | 0.90 | MAPK1 (0.51) | AXLEGFRMAPK1 | |
| SCHEMBL3450023 | 0.89 | MAPK1 (0.50) | AXLEGFRMAPK1 | |
| SCHEMBL3449638 | 0.89 | MAPK1 (0.50) | AXLEGFRMAPK1 | |
| SCHEMBL3450656 | 0.88 | MAPK1 (0.49) | AXLEGFRMAPK1ERBB2HPGD | |
| SCHEMBL3344180 | 0.87 | NPC1 (0.53) | EGFRAURKAAURKBMAPK1BRD4 | |
| SCHEMBL13310378 | 0.87 | BRD4 (0.52) | AXLEGFRMAPK1BRD4BCL6 | |
| SCHEMBL3449787 | 0.87 | ALK (0.54) | EGFRCTSCALK | |
| SCHEMBL3344452 | 0.87 | ABL1 (0.56) | AXLEGFRAURKAAURKBMAPK1 | |
| SCHEMBL3449507 | 0.86 | AXL (0.49) | AXLEGFRAURKAMAPK1ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | AXL 2812/4885EGFR 2771/4885AURKA 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.